Please use this link to access this publication.
Abstract
The widespread use of cannabis derived products has raised concerns with regard to their side effect profile, particularly hepatotoxicity. This case centers around a 45-year-old female patient receiving therapeutic cannabis oil, who demonstrated an acute surge in hepatic transaminases after excluding common etiologies, such as paracetamol and recent flucloxacillin, as both are hepatotoxic. A subsequent improvement in hepatic parameters following discontinuation reinforces the potential for an existing association between cannabis oil and liver injury. Furthermore, this case highlights the need for clinicians to recognize cannabinoid products as potential hepatotoxins, especially in patients with unexplained hepatic dysfunction. Given the growing access to such products, rigorous oversight and research have become essential in identifying potential health hazards and ensuring consumer safety.